E. Terzoli

发表

Aromatase inhibitors in post-menopausal metastatic breast carcinoma

M. Pino, M. Milella, F. Cognetti, 2007, Expert opinion on investigational drugs.

New aromatase inhibitors as second‐line endocrine therapy in postmenopausal patients with metastatic breast carcinoma

M. Mottolese, S. Di Cosimo, M. Milella, 2005, Cancer.

Questions about anastrozole for early breast cancer

R. Stasi, E. Terzoli, 2002, The Lancet.

Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.

M. Milella, F. Cognetti, F. Facciolo, 2006, Cancer treatment reviews.

Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients.

F. Cognetti, A. Fabi, P. Carlini, 2006, Cancer treatment reviews.

Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.

S. Di Cosimo, A. Fabi, P. Carlini, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

S. Cosimo, S. Di Cosimo, M. Milella, 2006, British Journal of Cancer.

Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up

M. Leandri, C. Garufi, E. Terzoli, 2006, European Neurology.

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients

I. Sperduti, E. Bria, C. Garufi, 2003, British Journal of Cancer.

Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?

A. Ceribelli, M. Mottolese, S. Di Cosimo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxanes with anthracyclines as first‐line chemotherapy for metastatic breast carcinoma

F. Cognetti, D. Giannarelli, F. Cuppone, 2005, Cancer.

Neoadjuvant chemotherapy for metastatic colon cancer: too much caution and still too much to be assessed.

A. Torsello, G. Ettorre, C. Garufi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin–paclitaxel in metastatic breast cancer patients

F. Cognetti, S. Tomao, I. Sperduti, 2007, Anti-Cancer Drugs.

Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?

M. Mandalà, F. Cognetti, A. Fabi, 2006, Chest.

Treatment of resected non-small-cell lung cancer.

D. Giannarelli, E. Bria, E. Terzoli, 2005, The New England journal of medicine.

Improving Quality of Life in Cancer Patients

E. Terzoli, E. Nisi, M. Ranuzzi, 2016 .

Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit

R. Gralla, F. Cognetti, D. Giannarelli, 2005 .

Factorial design for randomized clinical trials.

F. Cognetti, M. Di Maio, D. Giannarelli, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?

S. Tomao, I. Sperduti, F. Cuppone, 2007, Clinical breast cancer.

The prognostic value of soluble interleukin‐6 receptor in patients with multiple myeloma

R. Stasi, A. Pagano, E. Terzoli, 1998, Cancer.

Effective Control of CMF‐Related Emesis with High‐Dose Dexamethasone: Results of a Double‐Blind Crossover Trial with Metoclopramide and Placebo

D. Giannarelli, M. Nardi, E. Terzoli, 1989, American journal of clinical oncology.

Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.

F. Cognetti, P. Carlini, D. Giannarelli, 2007, Journal of the National Cancer Institute.

Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns.

S. Amadori, A. Newland, R. Stasi, 2005, The oncologist.

Personality, inner experience and compliance in advanced cancer patients treated with external pumps.

D. Giannarelli, P. Pugliese, C. Nisticò, 1995, The Journal of infusional chemotherapy.

Disease-free survival (DFS) as surrogate end point for overall survival (OS) in adjuvant aromatase inhibitors (AIs) trials for breast cancer (BC): Meta-analysis of 10 randomized clinical trials (RCTs) exploring the magnitude of the benefit

F. Cognetti, V. Lorusso, P. Carlini, 2007 .

Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients

M. Caterino, F. Lévi, D. Giannarelli, 2000, Anti-cancer drugs.

124 Addition of oxaliplatin (L-OHP®) to chronomodulated (CM) 5-fluorouracil (5-FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advance colorectal cancer (ACC)

F. Lévi, S. Brienza, C. Garufi, 1995 .

Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison.

F. Cognetti, D. Giannarelli, E. Bria, 2007, European urology.

Gemcitabine-based polychemotherapy for advanced pancreatic cancer (APC): Is it ready for prime time? A pooled analysis of 3,682 patients (pts) enrolled in 12 phase III trials.

A. Ceribelli, M. Pino, M. Milella, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?

M. Mandalà, F. Cognetti, A. Fabi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Magnitude of benefit of the addition of bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials.

M. Milella, F. Cognetti, F. Loupakis, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Skin testing and hypersensitivity reactions to oxaliplatin.

E. Bria, C. Garufi, A. Cristaudo, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunohemolytic anemia following oxaliplatin administration.

R. D'Attino, S. Vaglio, G. Girelli, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?

F. Cognetti, D. Giannarelli, E. Cortesi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.

G. Grasselli, L. Gianni, S. Cresta, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma.

G. Rasi, E. Garaci, P. Pierimarchi, 2000, Melanoma research.

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

M. Milella, F. Cognetti, P. Carlini, 2006, Cancer.

Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.

R. Gralla, M. Milella, F. Cognetti, 2009, Lung cancer.

Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients.

A. Pace, C. Nisticò, E. Terzoli, 1996, Journal of neurology, neurosurgery, and psychiatry.

Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?

M. Milella, F. Cognetti, P. Carlini, 2009, Cancer.

Recombinant human granulocyte‐macrophage colony‐stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes

S. Amadori, R. Stasi, A. Pagano, 1999, British journal of haematology.

Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues.

A. Rossi, S. Verma, G. Tonini, 2008, Expert opinion on biological therapy.

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer

S. Verma, M. Milella, K. Pritchard, 2008, Cancer.

A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer.

A. Marchetti, R. Sacco, F. Mucilli, 2009, Lung cancer.

Adjuvant Chemotherapy for Non-small Cell Lung Cancer

M. Milella, F. Cognetti, F. Cuppone, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients.

F. Cognetti, I. Sperduti, E. Bria, 2006, European journal of cancer.

Cancer‐related fatigue

S. Amadori, R. Stasi, P. Beccaglia, 2003, Cancer.

Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.

A. Crescenzi, R. Stasi, A. Pagano, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Differences in the Availability of New Anti-Cancer Drugs for Italian Patients Treated in Different Regions. Results of Analysis Conducted by the Italian Society of Medical Oncology (AIOM)

P. Tagliaferri, L. Crinò, G. Beretta, 2010, Tumori.

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

M. Milella, F. Cognetti, P. Carlini, 2008, Breast Cancer Research and Treatment.

Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study.

S. Brienza, C. Nisticò, C. Garufi, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Hormonal adjuvant treatment plus radiotherapy versus exclusive radiotherapy in locally advanced prostate cancer: Pooled analsys of 6 randomized trials.

M. Gallucci, M. Milella, F. Cognetti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly schedule of vinorelbine in pretreated breast cancer patients

M. Milella, A. Fabi, R. D'Attino, 2000, Breast Cancer Research and Treatment.

Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes.

S. Amadori, R. Stasi, E. Terzoli, 2002, Blood.

Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care.

M. Maltoni, M. Pirovano, O. Nanni, 1997, Journal of pain and symptom management.

Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.

M. Milella, F. Cognetti, D. Giannarelli, 2000, American journal of clinical oncology.

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.

E. Van Cutsem, L. Dirix, Y. Humblet, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study

F. Cognetti, I. Sperduti, F. Cuppone, 2007, Anti-cancer drugs.

Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors

M. Mottolese, F. Cognetti, D. Giannarelli, 2006, Anti-cancer drugs.

Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules.

M. Milella, F. Cognetti, A. Fabi, 2004, Journal of experimental & clinical cancer research : CR.

Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer.

S. Barni, L. Frontini, D. Giannarelli, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

An integrated psychological strategy for advanced colorectal cancer patients

A. Bottomley, D. Giannarelli, P. Pugliese, 2006, Health and quality of life outcomes.

P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance.

M. Diodoro, M. Mottolese, A. Torsello, 2008, European journal of cancer.

Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes.

S. Amadori, R. Stasi, E. Abruzzese, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.

S. Di Cosimo, A. Fabi, P. Carlini, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma

P. Vrignaud, F. Lévi, T. Granda, 2002, British Journal of Cancer.

Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study

S. Barni, L. Frontini, I. Sperduti, 2006, Anti-cancer drugs.

Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinoma

S. Cosimo, M. Milella, F. Cognetti, 2004, Cancer.

Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity

F. Cognetti, I. Sperduti, F. Cuppone, 2009, Anti-cancer drugs.

Weekly epirubicin plus lonidamine in advanced breast carcinoma

M. Milella, A. Fabi, C. Garufi, 1999, Breast Cancer Research and Treatment.

A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer

L. Frati, A. Romiti, G. Spinelli, 2006, BMC Cancer.

Taxanes as primary chemotherapy for early breast cancer

M. Milella, F. Cognetti, P. Carlini, 2008, Cancer.

A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer.

G. Silecchia, F. Lévi, C. Garufi, 1997, European journal of cancer.

Weekly Docetaxel in Pretreated Metastatic Breast Cancer Patients: A Phase I-II Study

S. Barni, L. Frontini, M. Milella, 2005, Oncology.

Quality of life and chronotherapy

P. Pugliese, C. Garufi, E. Terzoli, 2002, Chronobiology international.

Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues

A. Rossi, S. Verma, G. Tonini, 2008 .

Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer.

A. de Matteis, F. Perrone, E. Bria, 2005, Anticancer research.

Epidermal growth factor gene amplification is not frequent and cannot account for antitumor activity of cetuximab plus chemotherapy in advanced colorectal cancer patients.

M. Mottolese, A. Torsello, R. Merola, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress?

M. Pino, M. Milella, F. Cognetti, 2007, Cancer.

13-cis retinoic acid and interferon alfa-2a in the treatment of metastatic renal cell carcinoma.

E. Terzoli, A. Casali, L. Serrone, 1998, Journal of experimental & clinical cancer research : CR.

Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing.

S. Amadori, R. Stasi, E. Abruzzese, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5–16) in advanced colorectal cancer patients

G. Cappellini, D. Giannarelli, P. Pugliese, 2004, Journal of Cancer Research and Clinical Oncology.

Fixed dose‐rate gemcitabine infusion as first‐line treatment for advanced‐stage carcinoma of the pancreas and biliary tree

S. Di Cosimo, M. Milella, F. Cognetti, 2005, Cancer.

Non-small cell lung cancer: early stages.

U. Pastorino, A. Ceribelli, F. Cognetti, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Irinotecan and chronomodulated infusion of 5‐fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma

L. Dogliotti, R. D'Attino, M. Tampellini, 2001, Cancer.

Breast cancer and timing of surgery during menstrual cycle: a 5‐year analysis of 248 premenopausal women

M. Milella, F. Cognetti, A. Fabi, 1999, Breast Cancer Research and Treatment.

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree: series of 106 consecutive patients.

M. Milella, F. Cognetti, I. Sperduti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Health and Quality of Life Outcomes

P. Pugliese, C. Garufi, E. Terzoli, 2006 .

Malignant glucagonoma. New options of treatment.

F. Marandino, M. Carducci, E. Ferretti, 2006, Journal of experimental & clinical cancer research : CR.

CPT11 alternating with 5 fluorouracil (5 FU) folinic acid (FA): A multicentre phase II study in 1st line chemotherapy (CT) of metastatic colorectal cancer (CRC): Preliminary results

L. Dirix, Y. Humblet, F. Cognetti, 1997 .